Physician profile
Jerad M Dalton
NPI 1306835418
$20,049.49
in general payments reported to CMS, 2019-2025
33 companies · $2,002 in 2025
The $2,002 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $1,372 · 2021: $2,105 · 2022: $2,398 · 2023: $8,006 · 2024: $3,237 · 2025: $2,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,853 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,625 · Travel and Lodging: $1,754 · Education: $12.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,853.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,625.00 |
| Travel and Lodging | $1,754.39 |
| Education | $12.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $8,100.55 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $2,249.06 | 2019-2025 | Spravato |
| Abbvie INC. | $2,100.92 | 2021-2025 | Vraylar |
| Bausch Health US, LLC | $807.18 | 2019-2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $682.47 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $612.87 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $552.28 | 2020-2025 | Caplyta |
| Neos Therapeutics, LP | $543.80 | 2019-2025 | Adzenys Xr-Odt |
| Corium, LLC | $495.96 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $480.02 | 2019-2025 | Trintellix |
| Allergan, INC. | $390.20 | 2019-2020 | |
| Axsome Therapeutics, INC. | $332.11 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $298.92 | 2021-2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $278.92 | 2019-2025 | Rexulti |
| Adlon Therapeutics L.P. | $278.51 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $237.98 | 2019-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $191.60 | 2019-2023 | Belsomra |
| Neuronetics, INC. | $189.66 | 2019-2023 | Neurostar Tms Therapy System |
| Eisai INC. | $180.60 | 2020-2022 | |
| Noven Therapeutics, LLC | $178.32 | 2023-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $164.03 | 2022-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $160.15 | 2025 | Jornay Pm |
| Alkermes, INC. | $137.52 | 2021-2023 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $69.59 | 2023-2025 | Quviviq, Quviviq |
| Teva Pharmaceuticals USA, INC. | $68.36 | 2022-2025 | Austedo Xr, Austedo Xr |
| Owp Pharmaceuticals, INC. | $59.66 | 2023-2025 | Subvenite, Lamotrigine |
| Vertical Pharmaceuticals, LLC | $45.26 | 2019-2024 | Relexxii |
| Rhodes Pharmaceuticals L.P. | $41.91 | 2019 | |
| Brainsway USA INC | $32.32 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.68 | 2022 | |
| Alfasigma USA, INC. | $25.58 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $16.86 | 2019 | |
| Almatica Pharma LLC | $16.64 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerad Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.